financetom
Business
financetom
/
Business
/
Couche-Tard Misses Q4 Earnings Forecast; Increases Annual Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Couche-Tard Misses Q4 Earnings Forecast; Increases Annual Dividend
Jun 25, 2024 3:04 PM

05:34 PM EDT, 06/25/2024 (MT Newswires) -- Alimentation Couche-Tard Inc. ( ANCTF ) after trade Tuesday reported fiscal fourth-quarter earnings that were both down on the year earlier period, and missed forecast.

Excluding items, the global convenience store and gas-stop operator said adjusted earnings, excluding most one-time items. fell 32% to US$461.0 million, or US$0.48 per share, in the quarter ended April 28, down from US$698.0 million, or US$0.71 per share in the year-prior period

The result missed the consensus Capital IQ forecast for an adjusted profit per share of US$0.50.

Couche-Tard said the decrease in it earnings was primarily driven by lower road transportation fuel gross margin in the United States, the impact of one less week in the quarter compared to the year-prior period, and the impact on its investments and business acquisitions on depreciation and financial expenses, partly offset by the impact of a lower income tax rate on net earnings, as well as the contribution from acquisitions, which amounted to approximately $21.0 million.

It also reported total merchandise and service revenues of $4.1 billion, a decrease of 1.7%. Same-store merchandise revenues decreased by 0.5% in the United States, by 2.0% in Europe and other regions, and by 3.4% in Canada, all impacted by constraints on discretionary spending due to challenging economic conditions for low income consumers.

The company reported an increase in the annual dividend declared for fiscal 2024 of 25.5%, from C$0.53 to C$0.6650

Couche-Tard shares closed up $1.08 or near 1.4% at $79.50 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved